Status:
COMPLETED
To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Santen Pharmaceutical Co., Ltd.
Conditions:
Open-Angle Glaucoma
Ocular Hypertension
Eligibility:
All Genders
20-74 years
Phase:
PHASE2
Brief Summary
To investigate the intraocular pressure (IOP)-lowering effect and safety of DE-104 ophthalmic solution in patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Eligibility Criteria
Inclusion
- Diagnosed with primary open-angle glaucoma or ocular hypertension.
- Provided signed, written informed consent.
- If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.
Exclusion
- Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.
- Presence of any abnormality or significant illness that could be expected to interfere with the study.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00656240
Last Update
March 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Osaka, Japan
Osaka, Japan